Y-3 for Injection in the Treatment of Acute Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 998 participants.
Also called NCT06517173
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 998 participants
- Registry
-
NCT06517173
-
- Other papers using this trial's data
- Loberamisal for Acute Ischaemic Stroke (LAIS): a multicentre, randomised, double-blind, parallel, placebo-controlled phase III clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06517173. Randomized; triple masking; primary purpose treatment. Start 2024-07-24 (actual); primary completion 2025-04-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Y-3 for Injection in the Treatment of Acute Ischemic Stroke
- Acronym
- LAIS
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Y-3 for injection
- Intervention (Drug)
- Placebo control group
- Lead sponsor
- Beijing Tiantan Hospital
- Collaborator
- Neurodawn Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct06517173- Content hash
149b8bbec848b9967b250dde45fc1e276cc049b9f5ce1cd1fb15ac9fccad9ea1